Valproic Acid + Irinotecan + Simvastatin for Glioblastoma
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against tumors in patients with recurrent glioblastoma and adults with recurrent IDH-mutated gliomas
Who Is on the Research Team?
Adam Cohen, MD
Principal Investigator
Inova Health Care Services
Are You a Good Fit for This Trial?
This trial is for adults with glioblastoma or IDH-mutated gliomas that have come back after previous treatment. Participants should be in generally good health aside from their brain tumor and able to take oral medications.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Irinotecan
- Simvastatin
- Valproic Acid
Trial Overview
Researchers are testing a combination of three drugs—valproic acid, irinotecan, and simvastatin—to see if they can stop the growth or shrink tumors in people with recurrent brain cancers. All participants receive all three drugs.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Day1 VPA 40mg/kg/dose PO BID and simvastatin at 40mg PO daily Day2 VPA 40mg/kg/dose PO BID, simvastatin at 40mg PO daily, and irinotecan 180mg/m2 IV Day3-21 Continuous simvastatin starting at 40mg daily PO
Day1 VPA 40mg/kg/dose PO BID and simvastatin at 40mg PO daily Day2 VPA 40mg/kg/dose PO BID, simvastatin at 40mg PO daily, and irinotecan 180mg/m2 IV Day3-21 Continuous simvastatin starting at 40mg daily PO
Find a Clinic Near You
Who Is Running the Clinical Trial?
Inova Health Care Services
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.